Hong Kong-based Essex Bio-Technology has announced that its wholly-owned subsidiary, Majeton has entered into an exclusive Distribution Agreement with Osteopore, an Australian and Singapore based medical technology company, to promote and sell Osteopore's dental and oral maxillofacial products in Singapore.

Pursuant to the Distribution Agreement, Majeton will be the exclusive distributor of the Products for an initial period of 3 years, starting from 2023 to 2026. Majeton, a wholly owned subsidiary of Essex Bio-Technology, is a sales, marketing and distribution company of therapeutics, medical devices and nutraceuticals for the region of South East Asia.

Osteopore's innovative oral maxilla facial products are used in guided bone regeneration, immediate implant loading, and socket preservation. In unique situations, Osteopore may also make available customised regenerative implants for various oral maxillofacial reconstructions.

The Group believes that Majeton's strong commercial presence in Singapore will synergistically bring to market Osteopore's innovative products supported by advanced 3D printing technology for improved clinical outcomes in dental patients throughout Singapore's dental clinics, private and public hospitals.